Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia
Acta Haematologica · 2021 · 144 (1) · 74-81
DOI: 10.1159/000507012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Haematologica, online erschienen am 30.06.2020. Verfasst von Amanda L Olson und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, mshernandez@mdanderson.org. Hauptthemen laut MEDLINE: Chromosome Aberrations. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Acute myeloid leukemia (AML) patients not in remission and beyond first or second complete remission are considered allogeneic stem cell transplant (SCT) candidates. We present 361 patients who underwent SCT from matched related or unrelated donors between 2005 and 2013. The purpose was to identify a subgroup of patients with active disease at the time of transplant that benefit. Cox proportional hazards regression analysis was used for univariate and multivariate analyses to predict overall survival (OS). Variables considered were age, sex, SWOG cytogenetic risk group, bone marrow (BM) and peripheral blood (PB) blast percentage, regimen intensity, and type of AML. At a median of 26 months after transplantation, OS, progression-free survival (PFS), non-relapse mortality, and relapse rates were 26, 24, 23, and 48%, respectively. In a univariate analysis, risk cytogenetics (p < 0.001) and BM blasts >4% (p = 0.006) or any blasts in PB (p < 0.001) indicated worse OS. In a multivariate analysis, patients with <5% BM blasts or absence of circulating blasts and good or intermediate risk cytogenetics had significantly superior OS (46%), PFS (44%), and disease progression at 3 years. Based on these findings, patients not in remission with good or intermediate risk cytogenetics and low blast counts should be considered for SCT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, mshernandez@mdanderson.org.
- Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA.
Zitieren
APA
Olson, A. L., Saliba, R. M., Oran, B., Chen, J., Alousi, A., Ahmed, S., Bashir, Q., Ciurea, S. O., Hosing, C., Seon Im, J., Kebriaei, P., Khouri, I. F., Mehta, R., Nieto, Y., Parmar, S., Rezvani, K., Shah, N., Shpall, E., Srour, S. A., …, & Popat, U. R. (2021). Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematologica, 144(1), 74-81. https://doi.org/10.1159/000507012
Vancouver
Olson AL, Saliba RM, Oran B, Chen J, Alousi A, Ahmed S, et al. Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematologica. 2021;144(1):74-81. doi:10.1159/000507012
BibTeX
@article{Olson2021,
author = {Olson, Amanda L and Saliba, Rima M and Oran, Betul and Chen, Julianne and Alousi, Amin and Ahmed, Sairah and Bashir, Qaiser and Ciurea, Stefan O and Hosing, Chitra and Seon Im, Jin and Kebriaei, Partow and Khouri, Issa F and Mehta, Rohtesh and Nieto, Yago and Parmar, Simrit and Rezvani, Katy and Shah, Nina and Shpall, Elizabeth and Srour, Samer A and Qazilbash, Muzaffar and Andersson, Borje S and Champlin, Richard and Popat, Uday R},
title = {Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia},
journal = {Acta Haematologica},
year = {2021},
volume = {144},
number = {1},
pages = {74--81},
doi = {10.1159/000507012}
}
EUVIMED